Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-05
DOI
10.1038/srep29090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lupiwighteone induces cell cycle arrest and apoptosis and activates the Nrf2/ARE pathway in human neuroblastoma cells
- (2015) Jie Ren et al. BIOMEDICINE & PHARMACOTHERAPY
- Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
- (2015) M. E. M. Dolman et al. CLINICAL CANCER RESEARCH
- Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
- (2015) J Flynn et al. LEUKEMIA
- Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
- (2015) C. Hu et al. MOLECULAR CANCER THERAPEUTICS
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
- (2014) Huiyuan Zhang et al. APOPTOSIS
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
- (2014) Edmond Chipumuro et al. CELL
- Dinaciclib for the treatment of breast cancer
- (2014) Carmen Criscitiello et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase
- (2014) Yihui Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs
- (2014) Nadine Löschmann et al. Translational Oncology
- A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways
- (2014) J Cheng et al. Cell Death & Disease
- The two faces of Cdk8, a positive/negative regulator of transcription
- (2013) Josipa Nemet et al. BIOCHIMIE
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- Emerging drug profile: cyclin-dependent kinase inhibitors
- (2013) James S. Blachly et al. LEUKEMIA & LYMPHOMA
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
- (2013) T. K. Nguyen et al. MOLECULAR CANCER THERAPEUTICS
- The genetic landscape of high-risk neuroblastoma
- (2013) Trevor J Pugh et al. NATURE GENETICS
- CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
- (2013) C Delehouzé et al. ONCOGENE
- ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
- (2012) E. Mahoney et al. BLOOD
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
- (2012) A J Johnson et al. LEUKEMIA
- Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice
- (2012) Carmelo Quarta et al. MOLECULAR IMAGING AND BIOLOGY
- Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma
- (2012) Agnes Rasmuson et al. PLoS One
- Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma
- (2011) Christopher Abdullah et al. CELL CYCLE
- Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription
- (2011) Sonal M. Manohar et al. LEUKEMIA RESEARCH
- Immunology and immunotherapy of neuroblastoma
- (2011) Robert C. Seeger SEMINARS IN CANCER BIOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
- (2010) Kamil Paruch et al. ACS Medicinal Chemistry Letters
- Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
- (2009) J. J. Molenaar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
- (2008) S.-R. A. Hussain et al. BLOOD
- CDK9 a Potential Target for Drug Development
- (2008) Fernanda Canduri et al. Medicinal Chemistry
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search